Man Group
ALLO icon

Man Group’s Allogene Therapeutics ALLO Stock Holding History

Man Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
701,901
+547,218
+354% +$1.2M ﹤0.01% 1706
2026
Q1 		$377K Sell
154,683
-371,423
-71% -$744K ﹤0.01% 2153
2025
Q4 		$721K Buy
526,106
+244,054
+87% +$322K ﹤0.01% 1781
2025
Q3 		$350K Buy
282,052
+7,368
+3% +$8.78K ﹤0.01% 1960
2025
Q2 		$310K Buy
274,684
+88,588
+48% +$118K ﹤0.01% 1953
2025
Q1 		$272K Buy
+186,096
New +$351K ﹤0.01% 1961
2024
Q1 		– Sell
-13,800
Closed -$44.3K – 2106
2023
Q4 		$44.3K Buy
+13,800
New +$39.1K ﹤0.01% 2012
2023
Q3 		– Sell
-220,307
Closed -$965K – 1691
2023
Q2 		$1.09M Buy
+220,307
New +$1.19M ﹤0.01% 1365
2022
Q1 		– Sell
-48,576
Closed -$725K – 2170
2021
Q4 		$725K Sell
48,576
-3,996
-8% -$70.5K ﹤0.01% 1422
2021
Q3 		$1.35M Buy
+52,572
New +$1.25M ﹤0.01% 1279
2021
Q2 		– Sell
-54,202
Closed -$1.91M – 1940
2021
Q1 		$1.91M Sell
54,202
-49,404
-48% -$1.67M 0.01% 1121
2020
Q4 		$2.62M Sell
103,606
-17,776
-15% -$579K 0.01% 1100
2020
Q3 		$4.58M Buy
121,382
+6,835
+6% +$258K 0.02% 861
2020
Q2 		$4.91M Sell
114,547
-25,942
-18% -$938K 0.02% 669
2020
Q1 		$2.73M Buy
140,489
+89,722
+177% +$2.14M 0.02% 747
2019
Q4 		$1.32M Buy
+50,767
New +$1.4M ﹤0.01% 1437
2019
Q3 		– Sell
-15,181
Closed -$408K – 1768
2019
Q2 		$408K Sell
15,181
-18,619
-55% -$519K ﹤0.01% 1705
2019
Q1 		$977K Buy
+33,800
New +$981K ﹤0.01% 1587

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Man Group's ALLO Position: Q2 2026 in Review

Man Group increased its Allogene Therapeutics (ALLO) stake by 354% in Q2 2026, buying an estimated $1.2M and bringing the position to 701,901 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Man Group first reported a position in ALLO in Q1 2019 and has held it in 18 quarters since. The position peaked at $4.91M in Q2 2020. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Man Group held 701,901 shares of Allogene Therapeutics worth $1.46M as of Q2 2026.
  • Man Group bought 547,218 Allogene Therapeutics shares in Q2 2026, an estimated $1.2M.
  • Allogene Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1706 holding.
  • Man Group first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • Man Group's Allogene Therapeutics position peaked at $4.91M in Q2 2020.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.